The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.
News|Articles|September 26, 2025
AI in oncology: Fundamentals to full integration into your practice
Explore Tempus' latest advancements in artificial intelligence and how it is being applied in real-world oncology settings with Dr. Sanjay Juneja of Tempus and Dr. Debra Patt of Texas Oncology.
Advertisement
Advertisement
Related to this article
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.
The FDA indication for adagrasib plus cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer has been removed.
The updated tarlatamab label reduces post-infusion monitoring after each of the first two doses to 6 to 8 hours, down from 22 to 24 hours.
TLX101-Px, an FET-PET imaging agent, was FDA approved to differentiate treatment-related changes from recurrent or progressive glioma.
The FDA approved aminolevulinic acid hydrochloride plus PDT for the treatment of superficial basal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lutetium Lu 177 Dotatate Injection for SSTR+ GEP-NETs
2
FDA Withdraws Indication for Adagrasib Plus Cetuximab in Previously Treated, KRAS G12C–Mutated mCRC
3
Venetoclax-Based Regimens Show Lower TLS Rates in CLL vs MCL
4
Pirtobrutinib Elicits Responses After Covalent BTK Inhibitor Failure in R/R CLL
5